カルナバイオサイエンスの株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2020/10/23 | 1,247 | 1,265 | 1,215 | 1,257 | ±0 | ±0% | 171,300 |
2020/10/22 | 1,301 | 1,304 | 1,235 | 1,257 | -49 | -3.8% | 196,300 |
2020/10/21 | 1,305 | 1,328 | 1,300 | 1,306 | +12 | +0.9% | 178,600 |
2020/10/20 | 1,318 | 1,321 | 1,291 | 1,294 | -50 | -3.7% | 117,300 |
2020/10/19 | 1,285 | 1,349 | 1,285 | 1,344 | +30 | +2.3% | 326,200 |
2020/10/16 | 1,358 | 1,358 | 1,299 | 1,314 | -44 | -3.2% | 174,700 |
2020/10/15 | 1,421 | 1,421 | 1,347 | 1,358 | -69 | -4.8% | 200,500 |
2020/10/14 | 1,461 | 1,481 | 1,425 | 1,427 | -47 | -3.2% | 98,500 |
2020/10/13 | 1,450 | 1,480 | 1,448 | 1,474 | +19 | +1.3% | 67,400 |
2020/10/12 | 1,490 | 1,490 | 1,451 | 1,455 | -8 | -0.5% | 33,800 |
2020/10/09 | 1,431 | 1,468 | 1,421 | 1,463 | +23 | +1.6% | 59,000 |
2020/10/08 | 1,465 | 1,469 | 1,435 | 1,440 | -24 | -1.6% | 77,000 |
2020/10/07 | 1,474 | 1,486 | 1,461 | 1,464 | -35 | -2.3% | 51,700 |
2020/10/06 | 1,500 | 1,512 | 1,470 | 1,499 | +10 | +0.7% | 51,300 |
2020/10/05 | 1,465 | 1,502 | 1,454 | 1,489 | +31 | +2.1% | 49,600 |
2020/10/02 | 1,503 | 1,508 | 1,443 | 1,458 | - | - | 153,000 |
2020/10/01 | 0 | 0 | 0 | 0 | - | - | 0 |
2020/09/30 | 1,502 | 1,529 | 1,491 | 1,500 | -16 | -1.1% | 53,900 |
2020/09/29 | 1,471 | 1,533 | 1,471 | 1,516 | +38 | +2.6% | 91,700 |
2020/09/28 | 1,515 | 1,515 | 1,458 | 1,478 | -44 | -2.9% | 116,700 |
2020/09/25 | 1,520 | 1,548 | 1,519 | 1,522 | +2 | +0.1% | 69,800 |
2020/09/24 | 1,591 | 1,605 | 1,491 | 1,520 | -91 | -5.6% | 328,700 |
2020/09/23 | 1,600 | 1,620 | 1,582 | 1,611 | +2 | +0.1% | 77,200 |
2020/09/18 | 1,590 | 1,609 | 1,570 | 1,609 | +5 | +0.3% | 111,400 |
2020/09/17 | 1,625 | 1,627 | 1,580 | 1,604 | -17 | -1% | 117,800 |
2020/09/16 | 1,585 | 1,635 | 1,572 | 1,621 | +37 | +2.3% | 152,100 |
2020/09/15 | 1,540 | 1,590 | 1,530 | 1,584 | +34 | +2.2% | 99,000 |
2020/09/14 | 1,546 | 1,577 | 1,545 | 1,550 | +4 | +0.3% | 87,100 |
2020/09/11 | 1,529 | 1,547 | 1,508 | 1,546 | +13 | +0.8% | 111,400 |
2020/09/10 | 1,553 | 1,559 | 1,525 | 1,533 | +8 | +0.5% | 79,500 |
2020/09/09 | 1,500 | 1,569 | 1,500 | 1,525 | -10 | -0.7% | 182,500 |
2020/09/08 | 1,460 | 1,542 | 1,459 | 1,535 | +71 | +4.8% | 159,800 |
2020/09/07 | 1,499 | 1,499 | 1,452 | 1,464 | -11 | -0.7% | 94,300 |
2020/09/04 | 1,440 | 1,495 | 1,438 | 1,475 | -13 | -0.9% | 118,600 |
2020/09/03 | 1,460 | 1,506 | 1,421 | 1,488 | +26 | +1.8% | 167,400 |
2020/09/02 | 1,520 | 1,550 | 1,458 | 1,462 | +8 | +0.6% | 291,600 |
2020/09/01 | 1,370 | 1,454 | 1,370 | 1,454 | +72 | +5.2% | 146,900 |
2020/08/31 | 1,380 | 1,407 | 1,372 | 1,382 | +26 | +1.9% | 69,700 |
2020/08/28 | 1,399 | 1,411 | 1,351 | 1,356 | -55 | -3.9% | 134,300 |
2020/08/27 | 1,411 | 1,424 | 1,367 | 1,411 | -7 | -0.5% | 161,200 |
2020/08/26 | 1,403 | 1,435 | 1,394 | 1,418 | +45 | +3.3% | 169,100 |
2020/08/25 | 1,386 | 1,399 | 1,368 | 1,373 | -1 | -0.1% | 89,000 |
2020/08/24 | 1,377 | 1,377 | 1,337 | 1,374 | -3 | -0.2% | 97,400 |
2020/08/21 | 1,409 | 1,427 | 1,376 | 1,377 | -31 | -2.2% | 118,700 |
2020/08/20 | 1,400 | 1,453 | 1,391 | 1,408 | -6 | -0.4% | 118,700 |
2020/08/19 | 1,378 | 1,417 | 1,378 | 1,414 | +42 | +3.1% | 105,400 |
2020/08/18 | 1,369 | 1,376 | 1,354 | 1,372 | -7 | -0.5% | 77,000 |
2020/08/17 | 1,392 | 1,392 | 1,348 | 1,379 | +5 | +0.4% | 48,100 |
2020/08/14 | 1,345 | 1,386 | 1,345 | 1,374 | +27 | +2% | 54,500 |
2020/08/13 | 1,360 | 1,369 | 1,341 | 1,347 | -11 | -0.8% | 73,300 |
1001~
1050
件表示中 / 3586件
類似銘柄と比較する
現在ご覧いただいている「カルナバイオ」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
カルナバイオ | 31,000円 | -43.1% | - | 0.00% | - | 1.84倍 |
|
キナーゼタンパク質の販売や受託試験など創薬初期の支援事業が柱。キナーゼ阻害剤で創薬も |
ノイルイミューン | 17,300円 | -97.8% | - | 0.00% | - | 1.50倍 |
|
独自技術用いたCAR-T細胞免疫療法で抗がん剤を複数開発中。中外製薬とライセンス契約 |
日ケミファ | 151,100円 | +2.5% | - | 3.31% | 90.86倍 | 0.29倍 |
|
中堅後発薬メーカー。長期収載品の主力は痛風薬ウラリット。新薬開発、検査薬事業を中期強化 |
VIS | 89,000円 | +87.8% | +265.7% | 0.00% | 53.45倍 | 2.45倍 |
|
mRNA標的低分子創薬技術を製薬会社に提供。共同創薬研究などによる契約金収入が柱 |
クリングル | 84,500円 | +240.0% | - | 0.00% | - | 2.75倍 |
|
細胞の増殖、保護、修復などの機能があるHGFタンパク質を用いて、難治性疾患治療薬を開発 |
市場注目の銘柄
チャート関連のコラム